

Additional file 2: Table S1 Hazard ratios for hypocalcemia in the subgroup analysis on each bisphosphonate preparation (vs normal group)

Active Ingredient	Category	Number of patients ^a	Follow-up period (patient-year)	Number of cases ^a	Incidence rate ^a [95%CI] (/patient-year)	cHR ^b [95%CI]	aHR ^b [95%CI]
Alendronate sodium hydrate	Normal	1,390	283.57	<10	<0.035	-	reference
	Mild	4,120	1,141.09	17	0.015 [0.008-0.022]	1.32 [0.44-3.94]	1.66 [0.55-5.00]
	Moderate	2,192	598.27	11	0.018 [0.007-0.029]	1.63 [0.52-5.12]	2.31 [0.70-7.69]
	Severe	270	50.20	10	0.199 [0.076-0.322]	13.53 [4.24-43.16]	16.03 [4.68-54.96]
Etidronate disodium	Normal	<18	1.61	0	-	-	reference
	Mild	11	0.83	0	-	-	-
	Moderate	<10	0.28	0	-	-	-
	Severe	0	0.00	0	-	-	-
Ibandronate sodium hydrate	Normal	25	10.67	0	-	-	reference
	Mild	56	25.83	0	-	-	-
	Moderate	34	24.52	0	-	-	-
	Severe	<10	0.56	0	-	-	-
Minodronic acid hydrate	Normal	387	253.66	<10	<0.039	-	reference
	Mild	1,277	925.26	<10	<0.011	-	1.14 [0.13-10.23]
	Moderate	608	388.21	<10	<0.026	-	1.27 [0.12-13.98]
	Severe	60	33.80	<10	<0.296	-	29.23 [3.26-261.83]
Sodium risedronate hydrate	Normal	781	201.63	<10	<0.050	-	reference
	Mild	2,098	700.87	<10	<0.014	-	1.50 [0.17-13.45]
	Moderate	1,050	340.66	<10	<0.029	-	2.22 [0.23-21.36]
	Severe	82	11.52	<10	<0.868	-	24.38 [2.20-269.82]
Zoledronic acid hydrate	Normal	<10	3.87	0	-	-	reference
	Mild	51	32.35	<10	<0.309	-	-
	Moderate	<35	22.49	0	-	-	-
	Severe	<10	3.49	0	-	-	-

aHR: adjusted hazard ratio, cHR: crude hazard ratio, CI: confidence interval

^a When the number of patients was <10, an aggregated value was presented based on the MID-NET® publication rule, so that a specific number could not be identified.

^b aHR and cHR were calculated based on the Cox proportional hazards model and aHR was adjusted with the covariates (see “Methods”)